Cost‐Effectiveness Analysis of Surgical Strategies Versus Medical Management for Rheumatic Heart Disease in Rwanda
Journal of the American Heart Association · 2025
DOI: 10.1161/jaha.124.038365 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Journal of the American Heart Association, 2025. Verfasst von Vongai Mlambo und 10 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine Stanford University Stanford CA. Hauptthemen laut MEDLINE: Rheumatic Heart Disease, Heart Valve Prosthesis Implantation, Health Care Costs. Die Arbeit nennt 71 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background
One‐third of the global rheumatic heart disease burden lies in sub‐Saharan Africa, where 17% of patients with severe rheumatic heart disease die within 3 years without valve surgery. Surgery is often considered uneconomical, although this assumption is not grounded in cost‐effectiveness analyses.
Methods
We evaluated the cost‐effectiveness of mechanical valve replacement, bioprosthetic valve replacement, and valve repair compared with medical management for patients with severe rheumatic heart disease in Rwanda. Using a Markov model, we simulated disease progression, incorporating transition probabilities from a meta‐analysis of regional observational studies. Costs were calculated using microcosting, and health effects were measured in disability‐adjusted life‐years (DALYs). Cost‐effectiveness was defined by a willingness‐to‐pay threshold of United States dollars (USD) $2307 per DALY, which is 3 times Rwanda's gross domestic product per capita. A 3% discount rate for costs and DALYs was applied.
Results
Surgical strategies extended life expectancy from 7 to 11 to 13 years. Mechanical and bioprosthetic valve replacements were cost‐effective compared with medical management. Mechanical valve replacement was most efficient, averting 5.64 discounted DALYs for a lifetime discounted cost of USD $10 539.34, with an incremental cost‐effectiveness ratio of USD $1704 per DALY. Bioprosthetic valve replacement averted 5.27 discounted DALYs but incurred higher costs (USD $10 873.06). Valve repair only averted 3.30 DALYs despite being least expensive (USD $8790.19). Repair became the most efficient surgical strategy if valve degeneration rates dropped
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- School of Medicine Stanford University Stanford CA.
- Department of Cardiothoracic Surgery King Faisal Hospital Kigali Rwanda.
- Department of General Surgery University of Vermont Medical Center Burlington MD.
- King Faisal Hospital Kigali Rwanda.
- Team Heart Kigali Rwanda.
- Department of Cardiology King Faisal Hospital Kigali Rwanda.
ORCID-Profile: Vongai Mlambo, Hannah Rando, Lambert Ingabire, Ceeya Patton-Bolman, Evariste Ntaganda, Ralph Bolman, Yihan Lin
Zitieren
APA
Mlambo, V., Wang, S., Musoni, M., Rando, H., Ingabire, L., Patton-Bolman, C., Mukeshimana, G., Ntaganda, E., Bolman, R., Bendavid, E., & Lin, Y. (2025). Cost‐Effectiveness Analysis of Surgical Strategies Versus Medical Management for Rheumatic Heart Disease in Rwanda. Journal of the American Heart Association. https://doi.org/10.1161/jaha.124.038365
Vancouver
Mlambo V, Wang S, Musoni M, Rando H, Ingabire L, Patton-Bolman C, et al. Cost‐Effectiveness Analysis of Surgical Strategies Versus Medical Management for Rheumatic Heart Disease in Rwanda. Journal of the American Heart Association. 2025. doi:10.1161/jaha.124.038365
BibTeX
@article{Mlambo2025,
author = {Mlambo, Vongai and Wang, Songnan and Musoni, Maurice and Rando, Hannah and Ingabire, Lambert and Patton-Bolman, Ceeya and Mukeshimana, Gloria and Ntaganda, Evariste and Bolman, Ralph and Bendavid, Eran and Lin, Yihan},
title = {Cost‐Effectiveness Analysis of Surgical Strategies Versus Medical Management for Rheumatic Heart Disease in Rwanda},
journal = {Journal of the American Heart Association},
year = {2025},
doi = {10.1161/jaha.124.038365}
}
EUVIMED